Ticker Details
Geron Corporation Geron Corp is a biopharmaceutical company. It supports the clinical stage development of a telomerase inhibitor, imetelstat.
IPO Date:	July 31, 1996
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.13B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.11 | 2.91%
Avg Daily Range (30 D):	$0.06 | 3.61%
Avg Daily Range (90 D):	$0.05 | 3.41%

Institutional Daily Volume
Avg Daily Volume:	3.03M
Avg Daily Volume (30 D):	17.29M
Avg Daily Volume (90 D):	12.91M

Trade Size
Avg Trade Size (Sh.):	361
Avg Trade Size (Sh.) (30 D):	660
Avg Trade Size (Sh.) (90 D):	558

Institutional Trades
Total Institutional Trades:	2,905
Avg Institutional Trade:	$1.83M
Avg Institutional Trade (30 D):	$2.22M
Avg Institutional Trade (90 D):	$1.71M
Avg Institutional Trade Volume:	.64M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$2.21M
Avg Closing Trade (30 D):	$1.73M
Avg Closing Trade (90 D):	$1.39M
Avg Closing Volume:	818.8K

News

Apr 6, 2026 @ 12:00 PM Geron to Participate in the 25th Annual Needham Vi... Source: Na

Feb 25, 2026 @ 12:00 PM Geron Corporation Reports Fourth Quarter and Full ... Source: Na

Dec 11, 2025 @ 1:00 PM Geron Corporation Announces Strategic Restructurin... Source: Harout Semerjian

Dec 4, 2025 @ 5:20 PM Blood Cancer Therapeutics Reach Critical Commercia... Source: Prnewswire

Oct 23, 2025 @ 10:14 PM GERON (GERN) INVESTIGATION ALERT: Bragar Eagel & S... Source: Bragar Eagel & Squire, P.C.

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-.13	$-.05	$-.13
Diluted EPS	$-.13	$-.05	$-.13
Revenue	$183.88M	$48.02M	$183.88M
Gross Profit
Net Income / Loss	$-83.5M	$-28.86M	$-83.5M
Operating Income / Loss	$-68.59M	$-25.54M	$-68.59M
Cost of Revenue
Net Cash Flow	$-1.44M	$-.55M	$-1.44M
PE Ratio